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Abstract
Background: Every year, 30,000 babies are born with congenital hearing impairment in China. The
molecular etiology of hearing impairment in the Chinese population has not been investigated
thoroughly. To provide appropriate genetic testing and counseling to families, we performed a
comprehensive investigation of the molecular etiology of nonsyndromic deafness in two typical
areas from northern and southern China.
Methods:  A total of 284 unrelated school children with hearing loss who attended special
education schools in China were enrolled in this study, 134 from Chifeng City in Inner Mongolia
and the remaining 150 from Nangtong City in JiangSu Province. Screening was performed for GJB2,
GJB3, GJB6, SLC26A4, 12S rRNA, and tRNAser(UCN) genes in this population. All patients with SLC26A4
mutations or variants were subjected to high-resolution temporal bone CT scan to verify the
enlarged vestibular aqueduct.
Results: Mutations in the GJB2 gene accounted for 18.31% of the patients with nonsyndromic
hearing loss, 1555A>G mutation in mitochondrial DNA accounted for 1.76%, and SLC26A4
mutations accounted for 13.73%. Almost 50% of the patients with nonsyndromic hearing loss in
these typical Chinese areas carried GJB2 or SLC26A4 mutations. No significant differences in
mutation spectrum or prevalence of GJB2 and SLC26A4 were found between the two areas.
Conclusion: In this Chinese population, 54.93% of cases with hearing loss were related to genetic
factors. The GJB2 gene accounted for the etiology in about 18.31% of the patients with hearing loss,
SLC26A4 accounted for about 13.73%, and mtDNA  1555A>G mutation accounted for 1.76%.
Mutations in GJB3, GJB6, and mtDNA tRNAser(UCN) were not common in this Chinese cohort.
Conventionally, screening is performed for GJB2, SLC26A4, and mitochondrial 12S rRNA in the
Chinese deaf population.
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Introduction
Hearing impairment is the most common neurosensory
disorder in humans, with an incidence of approximately
one in 1000 children worldwide. About 50-60% of these
cases have a genetic cause [1]. In China, it has been esti-
mated that 30,000 babies are born with congenital hear-
ing impairment per 20 million live births every year [2].
Although some mutational hotspots involved in inherited
hearing impairment, such as GJB2  235 delC, SLC26A4
IVS7-2A>G, and mitochondrial DNA 1555A>G, have
been reported in Chinese deaf populations, the molecular
etiology of deafness in Chinese children has not been
investigated systematically, and effective genetic evalua-
tion strategies for hearing impairment are not available in
most areas of China. China is a large country with a pop-
ulation of 1.3 billion, of which 91% are Han ethnic peo-
ple. Comprehensive genetic analysis of deaf children in
different regions of China should be performed to obtain
epidemiological information to provide effective genetic
testing and accurate counseling.
The most common molecular defects in nonsyndromic
autosomal recessive deafness involve Connexin 26, a gap
junction protein encoded by the GJB2 gene [3-10]. More
than 150 mutations, polymorphisms, and unclassified
variants of GJB2 have been reported to account for the
molecular etiology of about 8-40% of patients with non-
syndromic hearing impairment http://davinci.crg.es/deaf
ness. However, almost 79% of patients with nonsyndro-
mic hereditary deafness in China do not have mutations
in GJB2 [11]. Indeed, mutations in other connexin genes,
such as GJB6 for Cx30 and GJB3 for Cx31, have been iden-
tified and shown to cause hearing impairment [12,13].
Sequence analysis of the GJB2 gene in subjects with auto-
somal recessive hearing impairment has revealed a puz-
zling problem in that a high number of patients carry only
one mutant allele. Some of these families showed clear
evidence of linkage to the DFNB1 locus, which contains
two genes, GJB2 and GJB6 [3,14]. Further analysis demon-
strated a deletion truncating the GJB6 gene, encoding con-
nexin 30, near GJB2  in heterozygous affected subjects
[15,16].
SLC26A4 also makes appreciable contributions to auto-
somal recessive nonsyndromic deafness, enlargement of
the vestibular aqueduct (EVA), and Pendred syndrome.
SLC26A4 encodes an anion (chloride/iodide) transporter
transmembrane protein, pendrin, which is expressed in
the thyroid, kidney, and cochlea [17,18]. DNA sequence
analysis identified more than 100 different mutations in
SLC26A4 [8,19-25]. It was reported that SLC26A4 muta-
tions accounted for approximately 5% of all cases of
prelingual deafness in East Asia, 5% of cases of recessive
deafness in south Asia [26], 3.5% in the UK, and 4% in the
Caucasian population with nonsyndromic hearing loss
[27].
Although the majority of cases with hereditary hearing
loss are caused by nuclear gene defects, it has become clear
that mutations in mitochondrial DNA (mtDNA) can also
cause nonsyndromic hearing loss [28,29]. The best stud-
ied of these mutations is the 1555A>G mutation in the
mitochondrial 12S rRNA gene. Another recently identi-
fied mutation in the mitochondrial 12S rRNA gene is the
1494C>T in the conserved stem structure of 12S rRNA
[30]. Other nucleotide changes at positions 961 and 1095
in the 12S rRNA gene have been shown to be associated
with hearing loss, but their pathogenic mechanisms of
action in the predisposition of carriers to aminoglycoside
toxicity are much less clear [31,32]. Several mutations
(7444G>A, 7445A>G, 7472insC, 7510T>C, 7511T>C,
and 7512T>C) in the mitochondrial tRNAser(UCN) gene are
also known to cause maternally inherited nonsyndromic
hearing loss by disrupting the tRNA structure and func-
tion [33-35]. The mtDNA 1555A>G mutation accounts for
a small fraction of patients with nonsyndromic hearing
loss, with frequencies between 0.6% and 2.5% among dif-
ferent Caucasian populations [36-40] and higher frequen-
cies in Asian countries (3.43%, 3%, and 5.3% in Chinese,
Japanese, and Indonesian cohorts, respectively) [41-43].
In the present study, we performed a comprehensive anal-
ysis of 6 prominent deafness-related genes, GJB2, GJB3,
GJB6,  SLC26A4,  mtDNA 12S rRNA,  and mtDNA
tRNAser(UCN), in 284 patients with early-onset, nonsyndro-
mic hearing impairment from unrelated families from
two typical Chinese areas, Chifeng City in northern China
and Nantong City in southern China, to investigate the
molecular etiology in order to provide effective risk assess-
ment and genetic counseling for hearing loss patients and
their families in China.
Materials and methods
Patients and DNA samples
A total of 284 deaf subjects from unrelated families were
included in this study; 134 were from Chifeng Special
Education School in Inner Mongolia, and 150 were from
Nantong Special Education School in JiangSu Province,
China. The Huanghe River is the demarcation line
between northern and southern China. Chifeng is a typi-
cal city in northern China with a population of 4.61 mil-
lion, and Nantong is a typical city in southern China with
a population of 7.74 million. Chifeng and Nantong are
moderate on the population scales in northern and south-
ern China, respectively. Chifeng and Nantong both have
long histories of 8000 years and at least 5000 years,
respectively. No significant population immigration has
occurred over the history of the two cities, and the genetic
backgrounds of the respective populations remain rela-Journal of Translational Medicine 2009, 7:79 http://www.translational-medicine.com/content/7/1/79
Page 3 of 12
(page number not for citation purposes)
tively intact. The two cities have relatively stable economic
development, and the living habits and cultural back-
ground of the populations are characteristic of northern
and southern China, respectively. This cohort of patients
consisted of 158 males and 126 females from 3 to 20 years
old with an average age of 12.30 ± 2.70 years. Ethnically,
the patients consisted of 243 Han, 31 Mongolian, 7 Man,
and 3 Hui Chinese. The study protocol was performed
with the approval of the ethnicity committee of the Chi-
nese PLA General Hospital. Informed consent was
obtained from all subjects prior to blood sampling. Par-
ents were interviewed with regard to age of onset, family
history, mother's health during pregnancy, and patient's
clinical history, including infection, possible head or
brain injury, and the use of aminoglycoside antibiotics.
All subjects showed moderate to profound bilateral sen-
sorineural hearing impairment on audiograms. Careful
medical examinations revealed no clinical features other
than hearing impairment. DNA was extracted from the
peripheral blood leukocytes of 284 patients with nonsyn-
dromic hearing loss and 200 region- and race-matched
controls with normal hearing using a commercially avail-
able DNA extraction kit (Watson Biotechnologies Inc,
Shanghai, China).
Mutational analysis
DNA sequence analysis of the GJB2 coding region plus
approximately 50 bp of the flanking intron regions, mito-
chondrial 12S rRNA (nt611 to nt2007), and tRNAser(UCN)
(nt7148 to nt8095) genes were amplified by PCR fol-
lowed by sequencing using the Big Dye sequencing proto-
col in all patients. The sequence results were analyzed
using an ABI 3100 DNA sequencing machine (Applied
Biosystems, Foster City, CA) and ABI 3100 Analysis Soft-
ware v.3.7 NT, according to manufacturer's protocol.
Patients with monoallelic GJB2 coding region mutation
were further tested for GJB2  IVS1+1G>A mutation or
defects in exon1 and basal promoter of GJB2, GJB6 309-
kb deletion, and deletion of the whole GJB6  coding
region. The presence of the 309-kb deletion of GJB6 was
analyzed by PCR [15,16]. A positive control (provided by
Balin Wu, Department of Laboratory Medicine, Children's
Hospital Boston and Harvard Medical School, Boston,
MA) was used for detection of GJB6 gene deletions.
Patients with two GJB2  mutant alleles, one dominant
mutant allele, or mtDNA  1555A>G mutation were not
analyzed for SLC26A4 mutations. The exons of SLC26A4
of the remaining 227 patients were sequenced individu-
ally starting from the frequently mutated exons until two
mutant alleles were identified.
Patients with two GJB2  mutant alleles, one dominant
mutant allele, mtDNA 1555A>G mutation, or verified EVA
were not analyzed for GJB3 mutations. The coding exon of
GJB3 was sequenced in the remaining 188 patients.
Two hundred controls with normal hearing were
sequenced to determine the presence of mutations and
polymorphisms in the GJB2, GJB3, and GJB6 genes and
mtDNA 12S rRNA and tRNAser(UCN). In addition, all con-
trols were screened for SLC26A4 mutations by DHPLC
followed by sequencing analysis.
CT scan and thyroid examination
Fifty-six of 59 patients with mutations or variants in
SLC26A4  were examined by temporal bone computed
tomography (CT) scan for diagnosis of EVA or inner ear
malformation based on a diameter of >1.5 mm at the
midpoint between the common crus and the external
aperture [28]. To evaluate Pendred syndrome, patients
positive for SLC26A4 mutations or variants were exam-
ined by ultrasound scan of the thyroid and determination
of thyroid hormone levels. These procedures were per-
formed at the Second Hospital of Chifeng City, Inner
Mongolia and hospitals affiliated with Nantong Univer-
sity, China. As perchlorate discharge testing is not a gen-
eral clinical practice in China, it was not used in this study.
Results
Among the 284 cases included in this study, 139 cases had
prelingual hearing loss, including 94 congenital cases.
Fifty-six cases showed postlingual hearing loss, with an
average age of onset of 3.01 ± 1.86 years. The age of onset
was unclear in the remaining 89 cases. In addition, 79
cases (22 prelingual cases and 57 postlingual cases) had
clear histories of administration of aminoglycoside, with
an average age of onset at 2.23 ± 1.71 years, and patients
without a history of aminoglycoside use showed a signifi-
cantly lower average age of onset of 0.75 ± 1.07 years (P <
0.001).
GJB2 gene mutations
Sequence analysis of the GJB2  gene indicated that 51
patients carried two confirmed pathogenic mutations,
and 1 patient had an R75W mutation, which has been
reported to cause autosomal dominant syndromic deaf-
ness with palmoplantar keratoderma [44] (Table 1).
Twenty-eight patients, including the 1 patient with auto-
somal dominant R75W mutation, were heterozygous for
one pathogenic mutant allele. Four patients were hetero-
zygous for one unclassified novel variant, the pathogenic-
ity of which has not been determined (Table 1). In
addition, 3 patients carried the heterozygous allele V37I,
about which there is debate regarding whether it is a path-
ogenic mutation or a polymorphism [8,45-47]. Thus,
29.23% (83/284) of the unrelated families of deaf
patients in typical areas in China had molecular defects in
GJB2, and 18.31% (52/284) had confirmed molecular eti-Journal of Translational Medicine 2009, 7:79 http://www.translational-medicine.com/content/7/1/79
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ology of nonsyndromic hearing impairment (51 auto-
somal recessive and 1 autosomal dominant) in the GJB2
gene.
Five frameshift (235delC, 299_300delAT, 176_191del16,
560_605ins46, and 155_158delTCTG) and two missense
(T86R and R75W) pathogenic mutations were found in
this cohort (Table 1). The most prevalent mutation in this
patient cohort was 235delC, which has also been reported
to be the most prevalent mutation in other Asian popula-
tions [6,46]. Thirty-one patients were homozygous for
235delC mutation, 14 were compound heterozygous with
another pathogenic mutation, and 20 were heterozygous
for 235delC mutation (Table 1). Four novel alterations
were identified, specifically, a frameshift pathogenic
155_158delTCTG mutation and three unclassified mis-
sense variants, V198M, V63L, and V153A (Tables 1).
Overall, 134 mutant alleles (including the unclassified
missense variants but excluding the V37I variant) were
identified in 83 unrelated patients. 235delC alone
accounted for 71.64% (96/134) of the total mutant alle-
les. Two mutations, 235delC and 299delAT, accounted for
85.07% (114/134) of the GJB2 mutations in our patients,
91% in another Chinese population [47], and 97% in a
Taiwanese population [48]. These detection rates were
higher among all the studies on the Asian deaf popula-
tions to date [6,10,45,46,48]. The V37I variant was con-
sidered a pathogenic mutation in Japanese studies, but it
was not found in any of the Korean control or patient
populations reported previously [6,10,46]. The frequency
of V37I in our deaf population was lower than that in our
control group (P < 0.05). T123N is an unclassified variant,
which was counted as a mutation in a previous Japanese
study but as a polymorphism in another study in Taiwan
[10,45]. We found three T123N alleles in our control sub-
jects but none in the patient group.
No variations in the GJB2  gene mutation spectra were
found among the different ethnicities of Chinese patients
in our study, with 235delC being the most common
mutation in all ethnic groups. The 299_300delAT muta-
tion was found in 15 Han, 1 Mon, and 1 Hui patient. The
deleterious 560_605ins46 mutation was found in 1 Man
patient. The 176_191del16 mutation was detected in 8
Han and 1 Mon patient, and 155_158 delTCTG was
detected in 1 Man patient. Four of 7 Man patients (57%)
Table 1: Genotypes of patients with mutations in the GJB2 gene
Allele 1 Allele 2
Nucleotide 
Change
Consequence or 
amino acid change
Category Nucleotide 
change
Consequence or 
amino acid change
Category Number of 
patients
c.235delC Frameshift Pathogenic c.235delC Frameshift Pathogenic 31
c.235delC Frameshift Pathogenic c.299_300delAT Frameshift Pathogenic 8
c.235delC Frameshift Pathogenic c.176_191del16 Frameshift Pathogenic 5
c.235delC Frameshift Pathogenic c.257C>G T86R TM2 Pathogenic 1
c.560_605ins46 Frameshift Pathogenic c.560_.605ins46 Frameshift Pathogenic 1
c.299_300delAT Frameshift Pathogenic c.176_191del16 Frameshift Pathogenic 4
c.176_191del16 Frameshift Pathogenic c.176_191del16 Frameshift Pathogenic 1
c.223C>T R75W EC1
Autosomal dominant
aPathogenic
PPK
c.79G>A, 
c.341A>G
V27I, E114G Polymorphism 1
c.235delC Frameshift Pathogenic - 20
c.299_300delAT Frameshift Pathogenic - 6
c.155_158delTCT
G
Frameshift Pathogenic - 1
c.592G>A bV198M TM4 Novel c.79G>A, 
c.341A>G
V27I, E114G Polymorphism 2
c.187G>T bV63L EC1 Reported - 1
c.458T>C bV153AEC2 Novel c.608T>C I203T Polymorphism 1
c.109G>A cV37I, TM1 cSee note - 2
c.109G>A cV37I cSee note c.79G>A, 
c.341A>G
V27I, E114G Polymorphism 1
c.79G>A, 
c.341A>G
V27I, E114G IC2 Polymorphism - 42
c.79G>A, 
c.341A>G
V27I, E114G Polymorphism c.79G>A, 
c.341A>G
V27I, E114G Polymorphism 2
c.341A>G E114G Polymorphism - 1
c.79G>A V27I TM1 Polymorphism - 8
c.79G>A V27I Polymorphism c.79G>A V27I Polymorphism 1
TM, transmembrane domain; EC, extracellular domain; IC, intracellular domain.Journal of Translational Medicine 2009, 7:79 http://www.translational-medicine.com/content/7/1/79
Page 5 of 12
(page number not for citation purposes)
and about 30% of patients from all other races [27.98%
(68/243) of Han, 32.3% (10/31) of Mon, and 33.3% (1/
3) of Hui] carried GJB2 mutations. No significant differ-
ences in GJB2 detection rate were found among these four
ethnic groups (χ2 = 2.4893, P = 0.4772).
We analyzed the GJB2  gene from 200 control subjects
with normal hearing and found three types of deleterious
mutation, 235delC, 299_300delAT, and 139G>T(E47X),
carried by 7 subjects in the heterozygous state. This sug-
gested a GJB2 mutation carrier rate of about 3.5% (7/200)
in the general population. Meanwhile, the carrier rates of
GJB2 mutation in Korea, Japan, Taiwan, among Ashkenazi
Jews, and in the Midwestern United States were reported
to be 2%, 2.08%, 2.55%, 4.76%, and 3.01%, respectively
[5,6,45,46,49].
None of our patients heterozygous for one GJB2 mutant
allele or the controls with normal hearing carried the
IVS1+1G>A mutation or variant in exon1 and basal pro-
moter of GJB2.
Mutations in GJB6
None of our patients heterozygous for one GJB2 mutant
allele or the controls with normal hearing had the known
309-kb deletion or other variant in the GJB6 gene.
Mutations in mtDNA 12S rRNA and tRNAser(UCN)
Five patients were found to carry the 1555A>G mutation,
and 4 patients carried the 1095T>C mutation in the
mtDNA 12S rRNA gene. Two patients were detected carry-
ing the 7444G>A mutation in the mtDNA tRNAser(UCN)
gene. All of the above 11 patients had a clear history of
aminoglycoside use. None of the remaining 68 patients
with history of aminoglycoside use had mutations in 12S
rRNA or tRNAser(UCN) in the mitochondrial genome. One
of the 2 patients with 7444G>A mutation was also
homozygous for the SLC26A4 IVS7-2A>G mutation and
was further verified to have EVA by temporal CT scan.
Thus, this patient may be only a 7444G>A carrier, with
defects in SLC26A4 being the main cause of hearing loss.
Two of the 200 control subjects were found to carry the
mtDNA 12S rRNA 1095T>C mutation, giving a carrier rate
of 1% (2/200). Statistical analysis showed no significant
difference in the incidence of the 1095T>C mutation
between the patient and control groups. No other muta-
tions were detected in the mitochondrial genome in the
controls. All the mutations found in the mitochondrial
genome were homogeneous.
Mutations in SLC26A4
Sequence analysis of the SLC26A4  gene in these 227
patients with hearing impairment identified 28 patients
with two confirmed pathogenic mutations (Table 2) and
one compound heterozygote for two unclassified variants,
Y375C and R470H, which are most likely pathogenic.
Twenty-one patients carried one SLC26A4 mutant allele,
and 2 patients carried novel unclassified missense vari-
ants, I491T and L597S, respectively, which are probably
pathogenic due to the changes in evolutionarily conserved
amino acids. Two patients carried V659L, including 1 who
was verified to have EVA by CT scan. Wang et al. reported
the pathogenicity of V659L in Chinese EVA patients [25].
Two unclassified heterozygous missense variants were
found, I235V and T67S. The 2 patients carrying these sin-
gle conserved amino acid changes had normal vestibular
aqueducts. These two missense variants are probably
benign, or these patients were only carriers of the muta-
tion and their hearing impairment had other etiologies.
One patient with normal results on temporal CT scan car-
ried a novel variant, IVS12-6insT, in the heterozygous
state. Analysis using the program NNSPLICE available at
http://www.fruitfly.org/seq_tools/splice.html did not pre-
dict gain or loss of a splice site with this variant, and it was
therefore also considered benign. Thus, mutations in
SLC26A4 were identified in 18.66% (53/284) of patients
with hearing impairment in typical areas of China, 29
with two mutant alleles and 24 with one mutant allele.
A total of seven different pathogenic mutations (IVS7-
2A>G, E37X, K77I, S391R, N392Y, T410M, H723R) and
five novel, probably pathogenic variants (Y375C, R470H,
I491T, L597S, and H723D) were found. The E37X muta-
tion that results in a premature stop codon and a trun-
cated protein less than 5% of the normal length is
predicted to be deleterious. The H723D mutation is
caused by nucleotide substitution, c.2167C>G, which was
predicted to be deleterious as a milder change at the same
amino acid residue, H723R, was shown to be the most
common pathogenic mutation in Japanese subjects.
Other missense mutations, K77I, S391R, N392Y, T410M,
and H723R, have been reported in patients with hearing
loss [24,25,50]. Y375C, R470H, I491T, L597S, and
H723D were considered pathogenic, as they are located in
an evolutionarily conserved region. The substituted
amino acids are structurally and functionally different
from those in the wild-type sequence, and Y375C, R470H,
I491T, and H723D have been found in patients with EVA
or other forms of inner ear malformation and were not
found in our normal controls.
The most common mutation in our patient cohort was the
aberrant splice-site alteration, IVS7-2A>G, for which 16
patients were homozygous, 4 were compound hetero-
zygous, and 17 were heterozygous. The IVS7-2A>G muta-
tion accounted for 64.63% (53/82, counting only the
definite pathogenic and most likely pathogenic variants)
of all SLC26A4 mutant alleles in this population (Table
2).Journal of Translational Medicine 2009, 7:79 http://www.translational-medicine.com/content/7/1/79
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Three novel silent variants were identified in the patients,
c.1905C>G (E635E), c.678T>C (A226A), and c.225C>G
(L75L), which were not detected in the control group.
To determine the carrier frequency in the general popula-
tion, SLC26A4 exons 2-21 of 200 individuals with normal
hearing were analyzed by DHPLC. Four IVS7-2A>G heter-
ozygotes and one silent variant, 2217A>G (Q739Q), were
found. The carrier rate of the SLC26A4 mutation in China
was estimated to be about 2%. Polymorphisms in the
SLC26A4 gene appear to be rare in the general population
in comparison to those in the GJB2 gene.
CT scan
Temporal CT scan revealed EVA and/or other inner ear
malformation in 39 patients. Twenty-eight patients had
EVA and two pathogenic mutant alleles, consistent with
an autosomal recessive disorder caused by biallelic loss of
function of pendrin protein. One female patient carrying
two novel missense variants, Y375C and R470H, had a
common cystic cavity of the cochlea and vestibule without
EVA. One male patient carrying a novel I491T variant had
enlarged vestibular aqueducts with Mondini dysplasia.
Eight patients with one mutant IVS7-2A>G allele had
EVA. One patient with one mutant 2168A>G allele had
EVA. CT scan results of 3 patients carrying heterozygous
IVS7-2A>G, N392Y, and a polymorphism (L75L), respec-
tively, were not available (Table 2). Temporal CT scan
Table 2: Genotypes of SLC26A4 gene-related hearing impairment in typical Chinese areas
Allele 1 Allele 2 Number of patients
Nucleotide 
Change
Amino acid 
change
Category Nucleotide 
change
Amino acid 
change
Category
c.IVS7-2A>G aberrant splicing Pathogenic c.IVS7-2A>G Aberrant splicing Pathogenic 16 EVA
c.2168A>G H723R Pathogenic c.2168A>G H723R Pathogenic 1 EVA
c.1174A>T N392Y Pathogenic c.1174A>T N392Y Pathogenic 1 EVA
c.IVS7-2A>G aberrant splicing Pathogenic c.230A>T K77I Pathogenic 1 EVA
c.IVS7-2A>G aberrant splicing Pathogenic c.1229C>T bT410M Pathogenic 1 EVA
c.IVS7-2A>G aberrant splicing Pathogenic c.1975G>C bV659L Pathogenic 1 EVA
c.IVS7-2A>G aberrant splicing Pathogenic c.2168A>G H723R Pathogenic 3 EVA
c.2168A>G H723R Pathogenic c.109G>T E37X, nonsense 
mutation
Pathogenic 1 EVA
c.2168A>G H723R Pathogenic c.1229C>T bT410M Pathogenic 1 EVA
c.2168A>G H723R Pathogenic c.2167C>G H723D Unclassified 
variant
1E V A
c.1173C>A S391R Pathogenic c.1229C>T bT410M Pathogenic 1 EVA
c.1124A>G Y375C Unclassified 
variant
c.1409G>A R470H Unclassified 
variant
1 Vestibular and cochlear 
malformation
c.1472T>C I491T Unclassified 
variant
1 EVA and Mondini
c.IVS7-2A>G aberrant splicing Pathogenic 8 EVA
c.2168A>G H723R Pathogenic 1 EVA
c.IVS7-2A>G aberrant splicing Pathogenic c.1905G>A E635E Silent
variant
1N D
c.1174A>T N392Y Pathogenic 1 ND
c.IVS7-2A>G aberrant splicing Pathogenic 8 nl
c.2168A>G H723R Pathogenic 2 nl
c.1790T>C L597S Unclassified 
variant
1n l
c.1975G>C bV659L Pathogenic 1 nl
c.757A>G I253V Unclassified 
variant
1n l
c.200C>G T67S Unclassified 
variant
1n l
c.IVS12-6i nsT Intron insertion Unclassified 
variant
1n l
c.225C>G L75L Silent variant 1 ND
c.678T>C A226A Silent variant 1 nl
c.1905G>A E635E Silent variant 1 nl
nl, normal; EVA, enlarged vestibular aqueduct; ND, not determined; NA, not available; IVS7, intravening sequence 7 (intron 7); IVS12, intravening 
sequence 12 (intron 12).Journal of Translational Medicine 2009, 7:79 http://www.translational-medicine.com/content/7/1/79
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results were normal in the remaining patients. Testing of
the two most frequent mutations, IVS7-2A>G and H723R,
identified 89.74% of patients with EVA or inner ear mal-
formation in this cohort.
Thyroid ultrasound and thyroid hormone assays
Thyroid ultrasound was performed to determine the pres-
ence or absence of goiter. None of the patients with
SLC26A4 mutations or variants showed the presence of
goiter. Only 1 patient with EVA showed cystoid changes in
the thyroid on ultrasound scan, whereas no changes were
observed in thyroid hormone levels. Thyroid hormone
assays showed that total T3 was slightly elevated in 2
patients, but this was of no clinical significance, according
to endocrinologists from Chinese PLA General Hospital.
Mutations in GJB3
Sequence analysis of the GJB3 gene identified five hetero-
zygous variants in 44 patients: 24_49ins26bp (GCCAT-
GGACTGGAAGACACTCCAGGC), 87C>T (F29F),
250A>G (V84I), 357C>T (N119N), and 497A>G (N166S)
(Table 3). Both 87C>T and 357C>T are silent variants.
Two patients were heterozygous for 250A>G (V84I). To
clarify the pathogenicity of the V84I variant, we per-
formed a control study in a group of 200 individuals with
normal hearing. The frequency of V84I in the deaf popu-
lation was not significantly different from that in the con-
trols, but it was shown to be a GJB3 polymorphism in the
Chinese population. One patient was heterozygous for
497A>G, which results in replacement of asparagine with
serine at position 166 of Cx31. The patient carrying
N166S mutation in one allele carried GJB2 235delC muta-
tion in the other allele. The 24_49ins26bp variant is a
novel frameshift, which results in a premature stop codon
and a truncated Cx31 protein. In addition, 24_49ins26bp
and N166S were detected only in patients with hearing
impairment and not in the controls, and they are very
likely to be deleterious mutations. Only 2 patients with
GJB3 mutation were found in this cohort.
Five types of GJB3 variant were detected in the control
group: 357C>T (N119N), 87C>T (F29F), 327C>T
(H109H), 250A>G (V84I), and 580G>A (A194T). One
control subject was homozygous for 250A>G (V84I).
327C>T is a silent variant. The variant 580G>A was pre-
dicted to replace the hydrophobic alanine at position 194
of Cx31 with a hydrophilic threonine (A194T). This vari-
ant was first found in 2 patients from China with auto-
somal dominant hearing loss and was considered to be a
genetic cause in these two cases [51]. We regard A194T as
an unclassified variant because it was not detected in any
of our patients. Long-term follow-up is necessary in the 2
controls with A194T mutation to determine whether their
hearing level will show any impairment in future.
Discussion
GJB2 gene
Previous reports suggested that the prevalence of GJB2
mutations varies among different ethnic groups. The most
common mutation in Caucasians, 35delG, was not found
in our patients. Instead, 235delC accounted for 71.64% of
GJB2 mutant alleles in our cohort. This is mutation is
detected at the highest rates among Asian populations,
with incidences of approximately 41% and 57% in two
Japanese reports, 67% in one Taiwanese study, and 73%
in one Korean study [6,10,45,46,48]. The Chinese popu-
lation is made up of six major ethnicities: Han, Man, Mon,
Hui, Zhuang, and Miao. The majority are Han (91.6%),
Table 3: Genotypes of patients and controls with variants in GJB3 gene
Allele 1 Allele 2 Domain Number of 
patientsd
Number of 
controls
Nucleotide 
Change
Consequence 
or amino acid 
change
Category Nucleotide 
change
Consequence 
or amino acid 
change
Category
c.24_49ins26bp Frameshift Novel 
pathogenic
- IC1 1
c.497A>G N166S Novel 
pathogenic
- EC2 1
c.580G>A A194T Unclassified - TM4 2
c.250A>G V84I Polymorphism - TM2 2
c.250A>G V84I Polymorphism c.250A>G V84I Polymorphism 1
c.357C>T N119N Polymorphism - IC2 39 38
c.357C>T N119N Polymorphism c.357C>T N119N Polymorphism 2
c.327C>T H109H Novel
Polymorphism
- IC2 1
c.87C>T F29F Polymorphism - TM1 1 2
TM, transmembrane domain; EC, extracellular domain; IC, intracellular domain.Journal of Translational Medicine 2009, 7:79 http://www.translational-medicine.com/content/7/1/79
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and this was also the predominant ethnicity in the study
population (85.56%). No significant differences in GJB2
mutation spectra were found among different ethnicities
in the Chinese population, although the numbers in the
non-Han populations were too small to allow final con-
clusions to be reached in our study.
The missense mutation T86R was found in 1 patient who
was also compound heterozygous for 235delC mutation.
Although this mutation is not listed in the GJB2 mutation
database website http://davinci.crg.es/deafness, it had
been reported in 3 Japanese patients [10]. The 15-year-old
Chinese female patient with R75W mutation developed
thickening and peeling of the skin at medial and lateral
sides of both hands and feet at 1 year of age. Pure-tone
audiometry testing showed that her father had moderate
high-frequency hearing loss, whereas her mother had nor-
mal hearing. Her father and mother did not have similar
skin problems. GJB2 sequencing indicated that neither of
her parents carried the R75W mutation. Therefore, R75W
was a de novo mutation in this subject. This mutation has
been reported previously in association with autosomal
dominant deafness and palmoplantar keratoderma [44].
Three missense variants, V63L, V153A, and V198M, likely
contribute to the pathogenesis of deafness, because they
were detected only in the patient group and not in the
control group, and they are evolutionarily conserved in
Xenopus, mouse, rat, sheep, orangutan, and human.
These mutations were heterozygous in 4 unrelated
patients who carried only one mutant allele. It is not clear
if they represent autosomal dominant mutations or are
autosomal recessive with an as-yet unidentified second
mutant allele in either the same gene (deep in introns or
untranslated regions) or in different genes (digenic syner-
gistic heterozygous mutations)[16,52]. Alternatively,
these patients may simply be coincidental carriers whose
deafness is caused by non-genetic environmental factors.
In our study population, 51 patients had two confirmed
pathogenic mutations, plus the patient carrying the dom-
inant R75W, and deafness in 18.31% (52/284) of our
patients was due to mutations in GJB2. The percentage of
GJB2-related hearing loss in other studies was 5.9-7% in
Taiwan, 4.8% in Korea, 10.3% in the US, 13.5% in Aus-
tralia, and 14.3% in Germany [6,8,9,45,48,53]. A signifi-
cant proportion of patients with GJB2 mutations had only
one mutant allele. Carriers of a single mutation in the
GJB2 gene show evidence of reduced hair cell function
[54]. Thus, it is possible that these carriers are more likely
than are non-carriers to develop hearing impairment in
the presence of other genetic defects or environmental fac-
tors. In addition to the common GJB6 309-kb deletion,
GJB2 IVS1+1G>A is another mutant DFNB1 allele. Tóth et
al. reported that 23.4% of Hungarian GJB2-heterozygous
patients carried the splice-site mutation IVS1+1G>A in the
5'UTR region of GJB2 [55]. In addition, GJB2 mutations
may act synergistically in the presence of mtDNA
1555A>G mutation with aminoglycoside-induced ototox-
icity [56]. Deletions in the GJB6  gene, the IVS1+1G>A
mutation, or variants in exon1 and the basal promoter of
GJB2  were not detected in any of the patients in the
present study.
SLC26A4 gene
SLC26A4 gene mutations were detected in nearly 20% of
our nonsyndromic hearing impairment patients, with
IVS7-2A>G being the most prevalent mutation. About
14% (39/284) of our cases were due to mutations in
SLC26A4. The SLC26A4 gene is another common gene
involved in deafness in typical areas in China. To identify
Pendred syndrome in the EVA patients, we performed thy-
roid hormone testing and ultrasound scan of the thyroid
to examine the function and structure of the thyroid
instead of perchlorate discharge testing, a routine method
used for examining thyroid function that is not available
in most areas of China. Our results indicated that none of
patients had Pendred syndrome. The discrepancy between
our results and those of previous studies may be explained
by differences in testing methods used; the age of the
patients, as those undergoing thyroid ultrasound and thy-
roid hormone assays in this study (3 to 20, average 12.3 ±
2.7) may have been too young to show symptoms; and/or
phenotypic diversity due to differences in genetic back-
ground.
It is interesting to note that the 10 patients with inner ear
malformation carried one missense mutation only.
Whether the missense mutation causes a dominant nega-
tive effect and/or specifies a different phenotype is not
clear. It is possible that the second mutant allele has not
yet been identified due to the location of mutations deep
in introns or promoter regions that were not sequenced,
intragenic exon deletions, or the involvement of muta-
tions in genes other than SLC26A4 in the pathogenesis
(i.e., digenic synergistic mutations).
The SLC26A4 mutation spectrum in typical areas in China
is similar to that reported in the overall Chinese popula-
tion but different from that in Japan. Research findings
indicate a gradient shift of the most prevalent mutation
from IVS7-2A>G to H723R from Chinese to Japanese,
respectively, with both mutations being equally prevalent
in the Korean population. This observation suggests that
IVS7-2A>G and H723R mutations may be ancient muta-
tions in China and Japan, respectively. A recent study by
Albert et al. of 100 unrelated patients with EVA in Euro-
pean Caucasian subjects revealed a diverse mutation spec-
trum without prevalent mutations, and only 40 patients
carried SLC26A4 mutations [24]. It is not clear why the
mutations in SLC26A4 account for a much lower percent-Journal of Translational Medicine 2009, 7:79 http://www.translational-medicine.com/content/7/1/79
Page 9 of 12
(page number not for citation purposes)
age of patients with EVA in Caucasian populations. Pre-
sumably, other genetic factors and environmental factors
are involved in the pathogenesis of EVA in Caucasian pop-
ulations.
We found no significant differences in the spectrum or
prevalence of GJB2 and SLC26A4 between patients from
Chifeng City and those from Nantong City.
mtDNA 12S rRNA and mtDNA tRNAser(UCN)
All 5 patients with 1555A>G mutation in the present
study had a history of aminoglycoside use. Pedigree anal-
ysis showed maternally inherited traits, and these patients
were diagnosed as having aminoglycoside-induced non-
syndromic hearing loss. We investigated the clinical and
molecular characteristics of three of the four mtDNA
1095T>C pedigrees. The extremely low penetrance of
hearing loss in the Chinese families carrying the 1095T>C
mutation strongly suggested that the 1095T>C mutation
itself is not sufficient to produce the clinical phenotype.
Therefore, other modifiers, including aminoglycosides,
nuclear genes, and mitochondrial haplotypes, are neces-
sary for the phenotypic manifestation of the 1095T>C
mutation. Despite the presence of several highly evolu-
tionarily conserved variants in protein-coding genes and
the 16S rRNA gene [57], the extremely low penetrance of
hearing loss with the 1095T>C mutation implies that the
mitochondrial variants may not have a modifying role in
phenotypic expression of the 1095T>C mutation in these
Chinese families. However, the history of exposure to
aminoglycosides in these 3 hearing-impaired subjects sug-
gested that these agents were probably the cause of hear-
ing loss. Two controls were also found to carry the
1095T>C mutation; they were advised to avoid use of
aminoglycosides, and their hearing level is being followed
closely.
The 7444G>A substitution has been described in deaf
individuals with and without the 1555A>G mutation, but
its pathogenicity has not been established [58]. Yao et al.
considered 7444G>A to be a normal polymorphism [59].
The patient with mtDNA 7444G>A mutation, who began
suffering bilateral hearing impairment within 3 months
after administration of streptomycin, had no relevant
family history. We performed PCR amplification of frag-
ments spanning the entire mitochondrial genome, and
subsequent DNA sequence analysis in this patient
revealed no variants in evolutionarily conserved regions
in the mitochondrial genome. The molecular etiology of
the patient carrying 7444G>A mutation remains to be
identified.
GJB3 gene
Richard  et al. [60] identified three mutations in the
Connexin31 gene (GJB3) in four families with erythroker-
atodermia variabilis (EKV). Independently, Xia et al. [13]
reported cloning of the human GJB3 gene on chromo-
some 1p33-p35 and found mutations in two small fami-
lies with deafness. The observation that some carriers of
GJB3 mutations showed a normal phenotype challenges
the involvement of these mutations in dominant deaf-
ness. GJB3 has been shown to be related to early-onset
autosomal recessive deafness. In the present study, the
patient carrying N166S mutation in one allele was verified
to carry GJB2 235delC mutation in the other. Direct phys-
ical interaction of Cx26 with Cx31 is supported by data
showing that Cx26 and Cx31 have overlapping expression
patterns in the cochlea. In addition, we identified the pres-
ence of heteromeric Cx26/Cx31 connexons by coimmu-
noprecipitation of mouse cochlear membrane proteins.
Furthermore, by cotransfection of mCherry-tagged Cx26
and GFP-tagged Cx31 into human embryonic kidney
(HEK)-293 cells, we demonstrated that the two connexins
were able to co-assemble in vitro in the same junction
plaque. The above data indicate that a genetic interaction
between GJB3 and GJB2 can lead to hearing loss [61]. A
diagnosis of digenic inherited GJB2 and GJB3 hearing loss
was made in this patient. The frameshift mutation
24_49ins26bp (GCCATGGACTGGAAGACACTCCAGGC)
generates a putative truncated protein of only 18 amino
acids. The patient carrying GJB3  24_49ins26bp in our
cohort had congenital symmetric hearing loss with no rel-
evant family history. The severity of her hearing impair-
ment was profound. Unfortunately, blood samples from
her parents were not available for analysis. If one of the
parents with normal hearing carries this mutation, the
patient may only be a carrier. Alternatively, if neither of
the parents with normal hearing carries this mutation, the
24_49ins26bp mutation in the patient may have arisen de
novo and may be the genetic cause or at least one of the
factors responsible for her phenotype.
Taken together, approximately 47.89% (83 + 53/284) of
patients with NSHI in typical Chinese areas had molecular
defects in the GJB2  or  SLC26A4  gene, whereas about
33.1% and 3.5% of European patients with NSHI carried
mutations in GJB2 and SLC26A4, respectively, with a total
of 36.6% in a patient cohort of 142 sib pairs [30]. MtDNA
1555A>G mutation accounted for the etiology in 1.76%
(5/284) of the patients with hearing loss. Ten patients
with a family history of hearing loss showed mutations in
GJB2, GJB3, GJB6, SLC26A4, mtDNA 12S rRNA, or
mtDNA tRNAser(UCN) in our study population. The etiolo-
gies of these 10 patients are most likely genetic, although
no mutations in common hearing loss genes were found.
If the 4 patients with 1095T>C in mtDNA 12SrRNA and 1
patient carrying GJB3 24_49ins26 were all included, hear-
ing loss in 54.93% (156/284) of our Chinese patients was
related to genetic factors.Journal of Translational Medicine 2009, 7:79 http://www.translational-medicine.com/content/7/1/79
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This is the first comprehensive study of the molecular eti-
ology of nonsyndromic hearing impairment in mainland
China. GJB2 and SLC26A4 are the two most common eti-
ologies for deafness in the Chinese population. A prelim-
inary investigation of the mutation spectrum and
prevalence of GJB2 and SLC26A4 between typical areas
from northern and southern China was performed in this
study, and no significant differences were found.
Conclusion
In this study, a total of 54.93% of Chinese patients with
hearing impairment showed evidence of genetic involve-
ment either based on genetic screening or family history,
and 18.31%, 13.73%, and 1.76% of the patients were
determined to have inherited hearing impairment caused
by  GJB2,  SLC26A4, and mtDNA  1555A>G mutations.
Mutations in GJB3, GJB6, and mtDNA tRNAser(UCN) are not
common. Screening for GJB2, SLC26A4, and 12S rRNA
should be considered the first step in genetic testing of
deaf Chinese patients. Furthermore, the molecular defects
of about 66% of the patients with nonsyndromic hearing
impairment in China remain to be identified.
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